Iproclozide (trade names Sursum, Sinderesin) is an irreversible and selective monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class that was used as an antidepressant, but has since been discontinued.[2] It has been known to cause fulminant hepatitis and there have been at least three reported fatalities due to administration of the drug.[3][4]
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.020.536 |
Chemical and physical data | |
Formula | C11H15ClN2O2 |
Molar mass | 242.70 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
See also
editReferences
edit- ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- ^ Suerinck A, Suerinck E (April 1966). "[Depressive states in a sanatorium milieu and monoamine oxidase inhibitors. (Therapeutic results by the combination of iproclozide and chlordiazepoxide). Apropos of 146 cases]". Journal de Médecine de Lyon. 47 (96): 573–586. PMID 5930723.
- ^ Pessayre D, de Saint-Louvent P, Degott C, Bernuau J, Rueff B, Benhamou JP (September 1978). "Iproclozide fulminant hepatitis. Possible role of enzyme induction". Gastroenterology. 75 (3): 492–496. doi:10.1016/0016-5085(78)90856-9. PMID 680506.
- ^ Kaplowitz N, DeLeve LD (2003). Drug-induced liver disease. Informa Health Care. p. 455. ISBN 0-8247-0811-3.